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A B S T R A C T
Objective: Deterioration in ventricular function is often observed in patients treated with anthracyclines
for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We
investigated whether prophylactic use of carvedilol can prevent doxorubicin-induced cardiotoxicity and
whether any observed effect is dose related.
Methods: A prospective, randomized, double-blind study in patients treated with doxorubicin, comparing
placebo (n = 38) with different doses of carvedilol [6.25 mg/day (n = 41), 12.5 mg/day (n = 38) or 25 mg/
day (n = 37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF)
from baseline to 6 months.
Results: LVEF decreased from 62  5% at baseline to 58  7% at 6-months (p = 0.002) in patients assigned
to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6
months, only one of 116 patients (1%) assigned to carvedilol had an LVEF < 50% compared to four of the 38
assigned to placebo (11%), (p = 0.013). No significant differences were noted between carvedilol and
placebo in terms of the development of diastolic dysfunction, clinically overt heart failure or death.
Conclusions: Carvedilol might prevent deterioration in LVEF in cancer patients treated with doxorubicin.
This effect may not be dose related within the studied range.
© 2018 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Anthracyclines are used to treat a wide spectrum of human
malignancies but their use is associated with an increased risk of
developing ventricular dysfunction that may be irreversible. Post-
chemotherapy left ventricularejectionfraction (LVEF) and cumulative
anthracycline dose are independent correlates of its occurrence. Early
detectionofcardiotoxicityanditsprompttreatmentmaybecrucial for
the preservation of cardiac function.1 Although the risk of cardiac
dysfunction is proportional to the cumulative anthracycline expo-
sure,2 a substantial number of patients still develop severe
cardiotoxicity at doses well below 550 mg/m2.3 In a study on the
early detection and prediction of cardiotoxicity, 27.6% of patients* Corresponding author at: King Saud bin Abdulaziz University for Health
Sciences, COM-J, King Abdul Aziz Medical City-WR, King Faisal Cardiac Center, Mail
Code 6599, P.O. Box 9515, Jeddah 21423, Saudi Arabia.
E-mail address: kinsaraaj@ngha.med.sa (A.J. Kinsara).
https://doi.org/10.1016/j.ihj.2018.06.011
0019-4832/© 2018 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).developed chemotherapy-related cardiotoxicity.4 Another study
found that doxorubicin in doses of less than 300 mg/m2 could induce
cardiotoxicity.5 Strategies that might prevent chemotherapy-induced
cardiomyopathy are receiving increased attention from oncologists
andcardiologists. However, there isa dearthofrandomized controlled
trialsreportedtodate.Theseincludecarvedilolwhichblocksβ1,β2and
α1-adrenergic receptors with antioxidant properties,6 metoprolol,
which only blocks β1 receptors, perindopril (an angiotensin convert-
ing enzyme inhibitor)7 and dexrazoxane, a chelating agent that is a
derivative of ethylene diamine tetra acetic acid, which reduces the
number of metal ions that can complex with anthracyclines and
thereforetheformationofsuperoxidefree-radicals.8 Tworandomized
trials, have reported that once-daily, low-dose carvedilol reduces the
development of ventricular dysfunction in patients treated for cancer
with doxorubicin or epirubicin.9,10
Accordingly, we conducted a prospective, randomized, double-
blind, placebo-controlled dose-ranging study to assess the
prophylactic use of carvedilol for preventing left ventricular
dysfunction in cancer patients treated with doxorubicin. India. This is an open access article under the CC BY-NC-ND license (http://
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This double-blind, randomized, placebo-controlled study was
conducted at the King Faisal Cardiac Centre in King Abdulaziz
Medical City-Jeddah, Saudi Arabia. The study was approved by a
local institutional review board. Patients were randomly assigned
to placebo or to one of three doses of carvedilol: 6.25 mg OD,
12.5 mg OD and 25 mg OD. Randomization was performed by an
independent statistician using computer generated random
number numbers and allocation concealment was achieved with
opaque sealed envelopes. Cancer patients aged >16 years who
were treated with doxorubicin and met the inclusion and exclusion
criterion were recruited for the study and were followed up for six
months. We conducted the study to observe the early anthracy-
cline cardiac toxicity (like all other similar trials), but late
anthracycline toxicity needs many years of follow-up, which could
be done, but with different protocol. Written informed consent
was obtained from each participant.
Exclusion Criteria: Patients with left ventricular ejection
fraction (LVEF) <50% before enrolment to the study, known
cardiomyopathy or on therapy for heart failure, bronchial asthma
that required regular daily beta-2 stimulant therapy, severe
peripheral arterial disease, second or third degree heart block,
severe valvular heart disease, earlier therapy with anthracycline
derivatives, coronary artery disease, thyroid function disorder and
patients who were on beta-blockers or angiotensin converting-
enzyme inhibitors were excluded.
Data were collected including a history, physical examinations,
electrocardiograms and echocardiograms at baseline and after 2, 4
and 6 months after initiation of doxorubicin. Mainly two-
dimensional (2D) echocardiography was used and only in few
cases, three-dimensional (3D) echo was done because 3D echo was
not routinely available at our center. LVEF, and left ventricular
diastolic (LVDd), and systolic diameters (LVSd) were measured
from 2D echocardiograms by two consultant cardiologists,
independently. An LVEF > 50% was considered normal. Doppler
ultrasound measures of LV diastolic dysfunction included the ratio
of E (early mitral inflow velocity) to A (late mitral inflow velocity),
mitral flow deceleration time (DT) and lateral E` on tissue Doppler
imaging. Diastolic dysfunction was graded using the American
Society of Echocardiography guidelines.11
3. Statistical analysis
The sample size calculation was based on the incidence of
doxorubicin-induced subclinical cardiomyopathy at 6 months of
27.6% in the control and a 4% in the carvedilol group patients,
reported in previous studies.4,9 The sample size was carried out
based on alpha value, statistical power, and effect size. The effect
size to detect reduction in the prevalence of doxorubicin-induced
subclinical cardiomyopathy was estimated from previous studies
to be 23.6%. Using a 2-sided α of 0.05, a sample size of 37 patients
per group in the study would provide 80% power to detect a 23.6%
difference in the prevalence of cardiomyopathy between control
and carvedilol groups. Statistical analyses were done by intention-
to-treat. Continuous variables were reported as mean  standard
deviations (SD) and categorical variables as frequencies and
percentages. Chi-square or Fisher’s exact tests were used to
compare categorical variables. Baseline measurements of the four
treatment groups were analyzed using one-way analyses of
variance (ANOVA) and paired Student’s t-test was used to compare
baseline and last visit (month 6) values for each of the treatment
groups with p < 0.05 considered statistically significant. The
primary analyses of interest were the differences in the change
in LVEF from baseline to six months for patients assigned to
placebo compared to carvedilol, regardless of dose and thenanalysis for a carvedilol dose-response. Missing data were imputed
using the last observation carried forward (LOCF) method.
The reproducibility of LVEF measurements was tested using
intra-class correlation coefficients (ICC). A total of 20 subjects were
randomly selected. Two independent observers were involved in
reading the echocardiography images. To determine intra-observer
reproducibility, the first observer performed two readings at two
different time points. To determine inter-observer reproducibility,
a second observer who was blinded to the results of the first
observer, provided independent readings on the same subjects.
4. Results
4.1. Baseline characteristics
One hundred and fifty-four patients were randomized to 4
groups (38 to placebo, 41 to carvedilol 6.25 mg OD, 38 to carvedilol
12.5 mg OD and 37 to carvedilol 25 mg OD); their baseline
characteristics are summarized in Table 1. Patient characteristics,
cardiac function, cancer type and cumulative doxorubicin dose was
similar amongst treatment groups.
4.2. Reproducibility assessment
Based on baseline data, the intra-observer variability, ICC, was
high: 0.975 (95% CI: 0.926–0.991) and the inter-observer variability
was 0.809 (95% CI: 0.509–0.925) for LVEF. Similarly, for follow-up
data, the intra and inter ICC were 0.955 (95% CI: 0.887–0.982) and
0.982 (95% CI: 0.995–0.993), respectively.
4.3. Treatment outcomes at end of six months
At 6 months, four (11%) patients assigned to placebo but only
one (1%) assigned to carvedilol 12.5 mg had an LVEF < 50%
(p = 0.013).
The cumulative doxorubicin dose in the five patients who
developed an LVEF < 50% were: 160 mg/m2 (one patient), 300 mg/
m2 (two patients) and 360 mg/m2 (one patient) in the placebo
group and 240 mg/m2 in one patient who received carvedilol
12.5 mg.
By six months, for patients assigned to placebo, LVEF had fallen
by 3.8  7.1% (p = 0.002) with 45% having some reduction in LVEF.
In contrast, there was no significant decline in LVEF for any
group assigned to carvedilol [6.25 mg (p = 0.059), 12.5 mg
(p = 0.100), or 25 mg (p = 0.073)] and depicted as bar and line
graphs in Figs. 1 and 2. On inter-group comparison, no significant
change was observed in LVEF between placebo and all carvedilol
groups (p = 0.185). Similarly, no difference noted in the inter group
comparison with any carvedilol dose: 6.25 mg (p = 0.080); 12.5 mg
(p = 0.219); or 25 mg (p = 0.060).
4.4. Effect of doxorubicin on LV size
At 6-months there was an increase in mean LVSd in patients
assigned to placebo from baseline of 28  4 mm to 31  6 mm
(p = 0.002) but not amongst patients assigned to carvedilol. The
differences between placebo and carvedilol, either in individual
dose groups or overall were not significant [6.25 mg (29  4 vs.
30  3, p = 0.059); 12.5 mg (29  4 vs. 30  4, p = 0.178); 25 mg
(30  5 vs. 31  4, p = 0.459)]. The mean changes in LVDd for
patients assigned to placebo or carvedilol were similar (Table 2).
4.4.1. Effect of doxorubicin on diastolic function
E' decreased only in patients treated with carvedilol 12.5 mg or
carvedilol 25 mg (Table 2). However, mean E' remained above 10
and mean E/E' ratio below 13 in all groups (8.0  4.0). Furthermore,
Table 1
Baseline Clinical Characteristics of Patients.
Carvedilol p-value*
Placebo (n = 38) 6.25 mg (n = 41) 12.5 mg (n = 38) 25 mg (n = 37)
Age (yrs) 40.4  14.0 46.1  13.0 41.3  18.2 42.0  15.0 0.345
Women (%) 76 80 58 77 0.119
BMI (kg/m2) 27.4  6.5 29.1  6.3 27.1  6.4 28.3  7.2 0.511
Baseline EF (%) 62.0  4.6 61.4  3.9 60.0  4.2 60.5  4.2 0.177
LVDd (mm) 45.3  5.3 46.0  5.1 44.8  4.3 44.6  6.3 0.634
LVSd (mm) 28.0  4.4 29.3  4.4 29.2  4.2 30.2  5.7 0.243
E/A (%) 1.2  0.4 1.2  0.5 1.3  0.5 1.2  0.3 0.836
E' 11.3  3.0 11.9  3.2 13.2  5.1 11.8  3.4 0.150
DT 190.8  33.8 200.6  28.2 203.6  38.7 199.5  38.8 0.421
E/E' 7.2  2.6 7.4  3.0 7.0  3.3 6.9  2.6 0.836
Cancer Type (%)
Breast 20 (53) 23 (56) 13 (34) 16 (43) 0.208
NHL 5 (13) 8 (20) 11 (29) 12 (33) 0.177
Other 13 (34) 10 (24) 14 (37) 9 (24) 0.502
Cum Doxo dose (mg/m2) 265.6  98.5 252  65.0 282  78.5 261.0  101.8 0.473
Hypertension 4 4 3 7 0.524
Diabetes Mellitus 6 8 5 8 0.712
Dyslipidemia 2 0 3 3 0.267
Data are mean  standard deviation or percentage. Cum Doxo dose and NHL denote cumulative doxorubicin dose and Non-Hodgkin Lymphoma respectively.
* P-value by ANOVA for continuous variables and Chi Square or Fisher’s test for categorical variables.
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were observed for patients assigned to placebo or carvedilol.
4.5. Mortality
Overall 11 patients died. Two deaths (5.3%) occurred on placebo,
one (2.4%) on carvedilol 6.25 mg, four (10.5%) on carvedilol
12.5 mg, and four (10.8%) on carvedilol 25 mg. Of these, 8 died
in hospital which was attributed to end stage cancer with
metastasis in addition to respiratory failure and massive pleural
effusion in some cases; and sepsis in other patients. We did not find
any significant difference in the hemodynamic response (blood
pressure and heart rate) between all carvedilol doses (see Table 4).
5. Discussion
This study provides further evidence that carvedilol may
provide protection against anthracycline-induced cardiomyopa-
thy. Moreover, this effect may be observed with a broad range of
carvedilol doses. This latter observation is important because the
side effects of beta-blockers appear strongly dose-related12 and
cancer patients may experience symptoms that might be ascribedFig. 1. LVEF at baseline and 6 months among different doses.to higher doses of beta-blocker. Lower doses of carvedilol may offer
myocardial protection but with fewer side effects.
Earlier, smaller randomized studies by Kalay et al. and Salehi et al.
suggested that carvedilol offered myocardial protection to cancer
patients treated with anthracyclines.9,10 Kalay et al. investigated the
protective effect of prescribing carvedilol 12.5 mg once daily to 50
patients treated with doxorubicin or epirubicin.9 There was no
attempt at blinding. Measures of both systolic and diastolic function
deterioratedlessamongst patientsassigned to carvedilol. Salehi etal.
conducted a study in 66 patients treated with doxorubicin or
epirubicin who were randomized to receive placebo, carvedilol
12.5 mg once daily or carvedilol 25 mg once daily. The paper does not
explicitly state whether or not the study was blinded. Overall, there
was no significant benefit with carvedilol but the authors claimed
that the lower dose was associated with improved diastolic function
and the higher dose with both improved diastolic and systolic
function. The prevention of Cardiac Dysfunction During Adjuvant
Breast Cancer Therapy (PRADA) trial results were recently reported.
They studied women with breast cancer in a double-blind, placebo-
controlled study with approximately 30 patients per group assigned
either to placebo, metoprolol succinate titrated to 100 mg/day or
candesartan titrated to 32 mg/day. Compared to those assigned to
placebo, patients assigned to candesartan had a smaller decline in
LVEF after chemotherapy (p = 0.03) but did not observe a similar
effect with metoprolol and questioned if other beta-blockers, such as
carvedilol, might have led to different results.13
Our study differs from previous trials of carvedilol in several
important ways. This is the first unequivocally, double-blind,
randomized, placebo-controlled study to investigate the effects of
carvedilol in patients treated with anthracyclines. It is the only
study to evaluate three doses of carvedilol and is also substantially
larger than the previous two studies (Table 3).9,10 In previous
randomized trials, the mean cumulative doxorubicin dose was
500 mg/m2 but only four patients received a cumulative
doxorubicin dose of >400 mg/m2 in our study, which may explain
the lower incidence of LV dysfunction in the control group in our
study. Doxorubicin cardiotoxicity is cumulative and typically
occurs at an average total dose of >500 mg/m2 but can occur at
cumulative doses as low as 300 mg/m2.
During six months of chemotherapy, four (11%) patients in the
placebo group but only one on carvedilol (3%) developed LV systolic
dysfunction (LVSD). Kalay et al. observed the development of LVSD
Fig. 2. Individual left ventricle ejection fraction at baseline and 6-months.
Table 2
Comparison of echocardiography and tissue Doppler variables at baseline and 6 month of follow-up.
Placebo p value Car (6.25 mg) p value Car (12.5 mg) p value Car (25 mg) p value
LVSd Baseline 28.0  4.4 0.002 29.3  4.4 0.059 29.2  4.2 0.178 30.2  5.7 0.458
6 months 30.7  5.7 30.4  3.0 30.3  4.3 30.9  4.1
LVDd Baseline 45.3  5.3 0.566 46.0  5.1 0.166 44.8  4.3 0.011 44.6  6.3 0.368
6 months 45.9  7.5 46.8  4.0 46.0  3.7 45.5  5.3
EF Baseline 62.0  4.6 0.002 61.4  3.9 0.059 60.0  4.1 0.100 60.4  4.2 0.073
6 months 58.2  6.6 60.0  2.9 58.2  6.6 59.2  2.8
E' Baseline 11.3  3.0 0.365 11.9  3.2 0.067 13.2  5.0 0.001 11.8  3.4 015
6 months 10.9  3.8 10.9  3.4 11.8  4.9 10.8  3.0
E/A Baseline 1.22  0.4 0.533 1.20  0.5 0.359 1.26  0.5 0.949 1.17  0.3 0.251
6 months 1.20  0.4 1.14  0.4 1.27  0.6 1.13  0.3
DT Baseline 190.7  33.9 0.188 200.8  28.2 0.637 203.6  38.7 0.228 199.5  38.8 0.139
6 months 199.7  39.8 197.1  30.0 213.3  45.1 209.3  40.9
E/E' Baseline 7.2  2.6 0.413 7.4  3.0 0.730 7.0  3.3 0.033 6.9  2.6 0.788
6 months 7.6  3.3 7.6  3.6 8.0  4.0 7.0  2.2
Car* stands for carvedilol.
Table 3
Comparison of studies on the prophylactic use of carvedilol in adult patients receiving anthracycline.
Studies
Present Kalay et al. Salehi et al. Total
Study Design
Single center Yes Yes Yes
Placebo controlled Yes Yes Yes
Blind Double Single NA
Treatment Groups 4 2 3
Sample Size
Placebo 38 25 22 85
Carvedilol 6.25 mg od 41 – – 41
Carvedilol 12.50 mg od 38 25 22 75
Carvedilol 25.00 mg od 37 – 22 59
Chemotherapy Treatment Doxorubicin Doxorubicin or epirubicin Doxorubicin or epirubicin
Cumulative Doxorubicin dose <400 mg/m2 520 mg/m2 530 mg/m2
Follow up period 6 months 6 months 4 months
Echo studies Baseline, then at 2, 4 & 6
months.
Baseline then after
chemotherapy.
Baseline, then only at 4
months.
Beneficial effect of carvedilol on LV function Yes Yes Yes
Number of patients who developed
cardiomyopathy
Placebo: 4 (11%)
Carvedilol: 1 (1%) (p = 0.013).
Placebo: 5 (20%)
Carvedilol: 1 (4%)
Placebo: 5 (23%).
Carvedilol: 6 (14%)
14/85 (16%)
8/145 (6%)
P < 0.01
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assigned to placebo and Salehi et al. in five patients (22.7%) treated
with carvedilol 12.5 mg/day but in only one (5%) treated with
carvedilol 25 mg/day and 5 (23%) patients in control group.
Cumulatively, including the current study, 14 of 85 patients (16%)
assigned to placebo developed LVSD compared to 8 of 145 patients
(6%) assigned to carvedilol (p < 0.01).We found no evidence to support a beneficial effect of carvedilol
on diastolic dysfunction; the incidence of different grades of
diastolic dysfunction were similar across treatment groups. This
finding differs from those reported in earlier studies.9,10 At 6
months, there was an increase in the E/E', which was statistically
significant in the carvedilol 12.5 mg group when compared to
baseline. In the PRADA study, the increase in E/E' on metoprolol
Table 4
Blood pressure and heart rate at baseline and 6 months for the 4 groups.
Group Dose Heart Rate Systolic BP Diastolic BP
Baseline 6-month Baseline 6-month Baseline 6-month
Placebo Mean 89.33 86.88 120.49 112.76 72.84 73.92
Carvedilol 6.25 mg Mean 87.08 84.89 129.47 119.64 74.44 73.21
Carvedilol 12.5 mg Mean 85.26 77.56 121.71 112.59 72.97 70.12
Carvedilol 25 mg Mean 85.45 81.79 120.53 116.78 72.41 74.11
S100 A.M. Abuosa et al. / Indian Heart Journal 70 (2018) S96–S100succinate was highly significant. Sympathetic activation increases
the velocity of myocardial relaxation and so it is not surprising that
beta-blockers may slow the rate of ventricular relaxation.
In clinical trials of heart failure, carvedilol was usually given
twice daily and in total daily doses of up to 100 mg/day. Whether
other doses or dosing regimens would carry greater benefit than
we observed should be considered in other trials. Whether, heart
rate rather than dose achieved is the more important target for
beta-blocker therapy is also uncertain.12–14 It is also unclear
whether similar effects would be observed with other beta-
blockers. Neither the study size nor the mechanistic character of
the primary outcome (change in LVEF) is sufficient to provide
conclusive evidence of clinically relevant benefits with carvedilol
for this population. However, this study does give hope for patients
with few alternatives, adds to the existing evidence-base and
provides valuable data to inform the design of definitive multi-
centre trials.
5.1. Study limitations
While this is the largest trial on the topic, including men and
women with different doses of carvedilol, it was still underpow-
ered to be able to detect a difference in outcomes between
treatment groups. Data was missed for troponin and creatinine
from a good percentage of patients. Long-term outcome was not
assessed.
5.2. Conclusion
These data provide further evidence suggesting that prophy-
lactic use of carvedilol might attenuate or prevent the decline in
LVEF associated with the use of anthracyclines for the treatment of
cancer.
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